Intracystic bleomycin for cystic craniopharyngiomas in children

Abstract

Editorial group: Cochrane Childhood Cancer Group. Publication status and date: New search for studies and content updated (no change to conclusions), published in Issue 7, 2016.

Multimodality Approach to a Pediatric Craniopharyngioma with Mixed Histological Features

“…Given that majority of pediatric CPGs are cystic in nature, the role of intralesional therapies has been proposed with objectives of postponing or sparing the adverse effects of conventional approaches [16,30,31]. An example is the administration of intracystic IFNα directly via an indwelling Ommaya reservoir into children with cystic CPGs by some overseas centers [16].…”

Multimodality Approach to a Pediatric Craniopharyngioma with Mixed Histological Features

“…Given that majority of pediatric CPGs are cystic in nature, the role of intralesional therapies has been proposed with objectives of postponing or sparing the adverse effects of conventional approaches [16,30,31]. An example is the administration of intracystic IFNα directly via an indwelling Ommaya reservoir into children with cystic CPGs by some overseas centers [16].…”

Craniopharyngioma: A comprehensive review of the clinical presentation, radiological findings, management, and future Perspective

“…Intracavitary chemotherapy with Bleomycin and IFN-α is preferred in CP patients. Ensuring the patient had no previous history of leakage, they are administered via Ommaya reservoir [ 45 , 52 , 53 ]. Bleomycin has been observed to decrease tumor size in the majority of patients.…”

“…Endocrine abnormalities are usually due to the original tumor but they also can be aggravated by the treatment. In the majority of patients, panhypopituitarism is present, which can manifest as adrenal insufficiency, hypothyroidism, hypogonadism, and/or growth hormone deficiency [ 52 ]. Hypopituitarism is managed by substituting deficient hormones.…”

Craniopharyngioma: Contemporary Management and Emerging Treatments

“…It is a polypeptide antibiotic (bleomycin A2 and B2) secreted by Streptomyces verticillus, inhibiting RNA and DNA synthesis. It was first reported in the treatment of craniopharyngioma in 1985 [45,46]. A dose of 1 to 15 mg of bleomycin is delivered through the Ommaya reservoir, often with stereotactic guidance.…”

Multimodality Approach to a Pediatric Craniopharyngioma with Mixed Histological Features

“…Given that majority of pediatric CPGs are cystic in nature, the role of intralesional therapies has been proposed with objectives of postponing or sparing the adverse effects of conventional approaches [16,30,31]. An example is the administration of intracystic IFNα directly via an indwelling Ommaya reservoir into children with cystic CPGs by some overseas centers [16].…”

Craniopharyngioma: A comprehensive review of the clinical presentation, radiological findings, management, and future Perspective

“…Intracavitary chemotherapy with Bleomycin and IFN-α is preferred in CP patients. Ensuring the patient had no previous history of leakage, they are administered via Ommaya reservoir [ 45 , 52 , 53 ]. Bleomycin has been observed to decrease tumor size in the majority of patients.…”

“…Endocrine abnormalities are usually due to the original tumor but they also can be aggravated by the treatment. In the majority of patients, panhypopituitarism is present, which can manifest as adrenal insufficiency, hypothyroidism, hypogonadism, and/or growth hormone deficiency [ 52 ]. Hypopituitarism is managed by substituting deficient hormones.…”

Craniopharyngioma: Contemporary Management and Emerging Treatments

“…It is a polypeptide antibiotic (bleomycin A2 and B2) secreted by Streptomyces verticillus, inhibiting RNA and DNA synthesis. It was first reported in the treatment of craniopharyngioma in 1985 [45,46]. A dose of 1 to 15 mg of bleomycin is delivered through the Ommaya reservoir, often with stereotactic guidance.…”

Multimodality Approach to a Pediatric Craniopharyngioma with Mixed Histological Features

“…Given that majority of pediatric CPGs are cystic in nature, the role of intralesional therapies has been proposed with objectives of postponing or sparing the adverse effects of conventional approaches [16,30,31]. An example is the administration of intracystic IFNα directly via an indwelling Ommaya reservoir into children with cystic CPGs by some overseas centers [16].…”

Craniopharyngioma: A comprehensive review of the clinical presentation, radiological findings, management, and future Perspective

“…Intracavitary chemotherapy with Bleomycin and IFN-α is preferred in CP patients. Ensuring the patient had no previous history of leakage, they are administered via Ommaya reservoir [ 45 , 52 , 53 ]. Bleomycin has been observed to decrease tumor size in the majority of patients.…”

“…Endocrine abnormalities are usually due to the original tumor but they also can be aggravated by the treatment. In the majority of patients, panhypopituitarism is present, which can manifest as adrenal insufficiency, hypothyroidism, hypogonadism, and/or growth hormone deficiency [ 52 ]. Hypopituitarism is managed by substituting deficient hormones.…”

Craniopharyngioma: Contemporary Management and Emerging Treatments

“…It is a polypeptide antibiotic (bleomycin A2 and B2) secreted by Streptomyces verticillus, inhibiting RNA and DNA synthesis. It was first reported in the treatment of craniopharyngioma in 1985 [45,46]. A dose of 1 to 15 mg of bleomycin is delivered through the Ommaya reservoir, often with stereotactic guidance.…”